Trento, Italy, June 26, 2018 - Currently, oncologists and cancer scientists face an abiding problem of major proportion, namely the emergence of resistance of certain cancers-some very common- to any therapy during their course. For some of these tumors, such as melanoma and kidney cancer, immune therapy has shown remarkable effects, but only a small fraction of patients undergo extended therapeutic responses. For prostate cancer patients whose tumors develop anti-androgen therapy resistance, further therapy has largely failed. And for cancers like Glioblastoma, pancreatic cancer, mesothelioma, small cell cancer and chemotherapy and marrow transplant-resistant acute myelogenous leukemia, a pathway to therapeutic success is not yet apparent. The thrust of this meeting will be to explore the molecular and biological sources of historical therapeutic resistance in these cancers and to assess the most promising opportunities for overcoming it.
Ugur Sahin will have a talk about 'Personalized Cancer Immunotherapy' on Tuesday June 26 during Session 4 - Therapeutically resistant Melanoma.
Further information is available at the organizer's website.
Mainz, 17. Mai 2018 - Jeder Tumor ist anders. "Krebs entsteht durch individuelle Mutationen", erklärt Prof. Dr. Ugur Sahin. "Wenn wir uns zum Beispiel den Lungenkrebs verschiedener Patienten anschauen, dann sind diese sehr unterschiedlich. Sie haben im Durchschnitt weniger als fünf Prozent der Mutationen gemeinsam, 95 Prozent sind ganz individuell. Herkömmliche Therapieansätze konzentrieren sich auf die fünf Prozent, sie schauen nur auf die Gemeinsamkeit. Sie sind gezwungen zu simplifizieren und zu generalisieren. Sie packen den Krebs in Schubladen, in die er nicht gehört."
Der ganze Artikel über das Forscherpaar Özlem Türeci und Ugur Sahin, sowie seine Bestrebungen in Mainz erschien im JGU Magazin.
Mainz, June 20, 2018 - Computational Analysis becomes ever more important for the advancement of personalized medicine. Bioinformatics accelerate the patient-centric molecular characterization of diseases and lead to a deeper understanding of the underlying mechanisms thus facilitating the development of novel drugs. Progress in Artificial Intelligence has a strong impact on clinical decision making in diagnosis and treatment. Nowadays, collection of huge amounts of data in the clinic and the lab is straight forward. However, the challenge lies within the analysis to draw the right conclusion from this big data.
Dr. Martin Löwer will give an impulse talk in session 'Data analysis for disease characterization and diagnostics'
For further information prease visit the organizer's website.
Ghent, Belgium, May 25, 2018 - VIB conference series hosts the MEDICAL BIOTECHNOLOGY focus meeting May 24-25, 2018, in Ghent Belgium. The conference features talks on new disruptive technologies for early diagnosis and more effective therapeutic intervention in established chronic diseases. Dr. Mustafa Diken will share years of experience in his talk "The evolution of RNA-based cancer vaccines" during plenary session "Biopharmaceutical Technology", May 25th.
For further information prease visit the conference website.
Mainz, May 15-17, 2018 – CIMT 2018 Annual Meeting
We are excited about the upcoming Annual Meeting of the Association for Cancer Immunotherapy (CIMT) in our hometown Mainz. Our scientists will be presenting their research in several sessions and look forward to discussing their projects.
Thursday, 17 May 2018, Short Talk Session IV Therapeutic Vaccination
- Local radiotherapy and E7-RNA-LPX vaccination activate non-redundant mechanisms and lead to complete tumor rejection of well-established HPV16+ TC-1 tumors (Nadja Salomon)
- Retrospective analysis of neoantigen prediction methods (Abstract 018, Martin Löwer)
- Local radiotherapy and E7-RNA-LPX vaccination activate non-redundant mechanisms and lead to complete tumor rejection of well-established HPV16+ TC-1 tumors (Abstract 027, Nadja Salomon)
- A two chain chimeric antigen receptor (CAR) scaffold recruits T-cell endogenous CD3 subunits for physiological CAR signaling and induces efficient tumor cell killing in vitro and in vivo (Abstract 167, Matthias Birtel, Ralf-Holger Voss)
- The Glioma Actively Personalized Vaccine Consortium (GAPVAC) presents the successful clinical translation of mutated peptide vaccination (Abstract 005)
- Successful completion of the Mutanome Engineered RNA Immuno-Therapy (MERIT) project (Abstract 010)
- E6/E7 RNA(LIP): An RNA cancer vaccine for treatment of patients with HPV16-positive malignancies (Abstract 012)
- A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for immunotherapy of malignant melanoma (Abstract 014)
Mainz, Germany, April 18, 2018 – Ugur Sahin, Scientific Director at TRON, has been awarded one of the prestigious ERC Advanced Grants 2017 for his project ‘SUMMIT - Stepping Up mRNA Mutanome Immunotherapy’, totaling 2.5 Million Euros over 5 years.
The ERC Advanced Grants are awarded to well-established, leading principal investigators to pursue ground-breaking projects. SUMMIT is one of the 269 projects proposed for funding out of 2,167 submitted proposals within the 2017 application round.
Read more about the ERC Advanced grants and see the complete list of awardees here.
TRON in the Media
Welcome to TRON
TRON – Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz is a biopharmaceutical research organization that pursues new diagnostics and drugs for the treatment of cancer and other severe diseases with high medical need. A focus of TRON is the development of novel platforms for individualized therapies and biomarkers, translating basic research into drug applications. TRON partners with academic institutions, biotech companies and the pharmaceutical industry, executing research with leading-edge technologies and supporting the development of innovative drugs to promote human health.